Welcome to our dedicated page for The Oncology Institute news (Ticker: TOI), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute reports developments in value-based community oncology care, combining oncology and hematology services with specialty pharmacy, patient services, clinical trials, transfusions, and related care models. Its updates center on operating results, specialty pharmacy volume, gross profit and cash flow trends, and the performance of capitated and Medicare Advantage payor relationships.
Company news also covers participation in CMS oncology payment models, contract expansion across community oncology markets, clinical pathway and provider engagement initiatives, investor conference appearances, and governance or compliance leadership changes. The business operates through Specialty Pharmacy, Patient Services, and Clinical Trials and Other segments.
The Oncology Institute (NASDAQ: TOI) appointed Kim Tzoumakas to its Board of Directors, effective February 23, 2026.
Ms. Tzoumakas brings more than two decades of executive leadership in oncology, pharmacy services and healthcare operations, currently serving as CEO of VytlOne National Pharmacy Services and with prior CEO and board experience.
The Oncology Institute (NASDAQ: TOI) reaffirmed 2025 guidance and provided a preliminary 2026 outlook on Jan 12, 2026. For 2026 the company expects total revenue of $630 million to $650 million, ~28% growth from the 2025 midpoint, including about $150 million of Capitation revenue.
TOI forecasts Adjusted EBITDA of $0 million to $9 million for 2026 (midpoint would be its first full year of Adjusted EBITDA profitability as a public company) and says profitability from newly onboarded delegated contracts will build through 2026 with fuller economics in 2027.
Longer term, TOI targets ~20% annual revenue growth through 2028, expects Capitation and Dispensary to be ~30% and 50% of revenue respectively, and projects margins expanding to the mid-single-digit range by 2028.
The Oncology Institute (NASDAQ: TOI) announced on Jan 9, 2026 the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer.
Panda brings more than 25 years of IT, digital transformation, cybersecurity, and enterprise software experience, with prior leadership roles at Cisco and Infosys; he will lead TOI’s technology strategy, including AI-enablement and enterprise data privacy and security practices. Mariano, with 18 years in people operations, joined TOI in 2022 and will oversee HR Operations, Total Rewards, Learning and Development, and Talent Acquisition.
CEO Dr. Daniel Virnich said the promotions support TOI’s growth and its focus on technology-enabled, value-based community cancer care.
The Oncology Institute (NASDAQ: TOI) announced that Mark Stolper joined its Board of Directors, effective January 2, 2026. Stolper currently serves as Executive Vice President and Chief Financial Officer of RadNet (NASDAQ: RDNT), a role he has held since 2004, and has prior board experience at public and private healthcare companies including 21st Century Oncology Holdings.
The company highlighted Stolper's expertise in capital markets, fundraising, strategic financial planning and payor strategy as supporting TOI's next phase of growth. Stolper commented that he expects TOI to pursue continued growth and profitability while focusing on cost-effective cancer care and improved patient outcomes.
The Oncology Institute (NASDAQ: TOI) announced that Gabe Ling resigned from the Board of Directors, effective December 1, 2025. The company said a formal search has begun to add independent directors with healthcare, clinical, and value-based care expertise.
The board emphasized thanks for Ling’s service during the company’s early public-market years and stated a continuing focus on strengthening governance and recruiting strategic, experienced members to support long-term growth.
The Oncology Institute (NASDAQ: TOI) reported Q3 2025 results and raised full‑year guidance on Nov 13, 2025. Consolidated revenue was $136.6M, up 36.7% year‑over‑year; gross profit was $18.9M, up 31.7%. Retail pharmacy set fill records, contributing $75.9M revenue and $12.8M gross profit in Q3. Net loss was $16.5M and basic/diluted loss per share was $0.14. Adjusted EBITDA improved to $(3.5)M in Q3; cash and cash equivalents were $27.7M at quarter end.
TOI updated 2025 guidance: revenue to $495–505M (from $460–480M) and Adjusted EBITDA to $(11)–$(13)M (from $(8)–$(17)M); Q4 Adjusted EBITDA is expected around $0–$2M. The company noted continued organic growth in Florida and Oregon and a new CAO hire for operations and AI enablement. A conference call and webcast were scheduled for Nov 13, 2025 at 5:00 p.m. ET.
Ascertain and The Oncology Institute (NASDAQ: TOI) announced a co-development to deploy a “near-touchless” prior authorization workflow using Ascertain’s Unified Payer Portal.
The joint team moved from signed statement of work to a live early-stage deployment in eight weeks, with the system live since September 2025. Pilot sites saw a >80% reduction in office-visit authorization submission time and the program freed hundreds of staff hours each week. The portal now processes prior authorizations across TOI’s 100+ clinics and affiliates. TOI estimates the initiative could yield up to $2 million in operating expense savings in 2026 as the solution scales to additional authorization types.
The Oncology Institute (NASDAQ: TOI) will release its third quarter 2025 financial results after market close on Thursday, November 13, 2025.
A company conference call will follow the same day at 5:00 p.m. Eastern Time, accessible by phone or simultaneous webcast on the company Investor Relations website. A replay will be available two hours after the call through Thursday, November 20, 2025. The passcode for both the live call and replay is 13756737.
The Oncology Institute (NASDAQ:TOI), a leader in value-based community oncology care, will participate in the Noble Capital Markets Emerging Growth Virtual Equity Conference. CEO Dr. Daniel Virnich and CFO Rob Carter will deliver a presentation on October 8, 2025 at 11:00 AM ET.
Investors can access the presentation webcast by registering through the company's Investor Relations website at investors.theoncologyinstitute.com.
The Oncology Institute (NASDAQ: TOI) has partnered with Protocol Behavioral Health to integrate mental health services into cancer care delivery. The collaboration aims to address the significant mental health challenges faced by cancer patients, with research showing that approximately 30% of cancer patients experience depression or anxiety.
Through this partnership, TOI patients will receive immediate access to specialized mental health services, offered in multiple languages and fully integrated into their cancer treatment plans. The partnership utilizes the Collaborative Care Model (CoCM), an evidence-based framework for team-based care delivery that has been shown to improve treatment adherence, quality of life, and patient satisfaction.